ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Equities
1541
CNE100006624
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
13.92 HKD | -0.57% |
|
-1.69% | -53.44% |
06-24 | ImmuneOnco Biopharmaceuticals Gets IND Approval for NMOSDs Drug Trial in China | MT |
06-03 | ImmuneOnco Biopharmaceuticals Gets China's Phase 3 Trial Approval for Leukemia Drug | MT |
![Consensus](/images/consensus_flch.gif)
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-53.44% | 671M | |
+16.45% | 122B | |
+21.96% | 116B | |
+23.73% | 27.03B | |
-20.05% | 20.36B | |
-16.28% | 15.91B | |
-16.52% | 16.43B | |
-44.35% | 15.6B | |
+63.91% | 14.94B | |
+2.52% | 13.59B |
- Stock Market
- Equities
- 1541 Stock
- News ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- ImmuneOnco Biopharmaceuticals Gets Nod to Trial Cancer Drug